Research
Hormonal
Cardiometabolic Syndrome (CMS) is an independent predictor of cardiovascular mortality and morbidity in older adults, with risk increasing as the number of CMS components increases.
Regularly check all components of Cardiometabolic Syndrome (blood pressure, blood sugar, lipids, waist circumference). Managing all of them together is more effective for preventing heart disease and stroke than treating just one.
GoodSupportsHIGH confidence
The presence of CMS by the NCEP ATP III definition was an independent predictor of the occurrence of a cardiovascular event after 4.1-year follow-up (38% increased risk), even after adjustment for traditional cardiovascular risk factors and considering each individual domain of CMS.
Why this rating
Based on multiple cohort studies and meta-analyses.
Source
The Cardiometabolic Syndrome and Sarcopenic Obesity in Older Persons
Ligia J. Domínguez et al. · Journal of the CardioMetabolic Syndrome · 2007
DOI 10.1111/j.1559-4564.2007.06673.x
narrative_reviewCited 185×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sarcopenic obesity (concurrent loss of muscle mass/strength and central obesity) significantly increases the risk of disability and mortality in older adults compared to obesity or sarcopenia alone.Good
- Intentional weight loss (5-10% of body weight) through combined diet and exercise improves metabolic health, reduces inflammation, and decreases the incidence of CMS in older adults.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →